NYSE:MYOV - Myovant Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$21.41 +0.07 (+0.33 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$21.34
Today's Range$21.07 - $21.76
52-Week Range$13.64 - $27.45
Volume48,900 shs
Average Volume66,611 shs
Market Capitalization$1.52 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.68
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. Myovant Sciences Ltd. has partnership with Flo Health to create a digital tool to screen for heavy menstrual bleeding. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Receive MYOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:MYOV
CUSIPN/A
Phone44-20-3318-9709

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.66 per share

Profitability

Miscellaneous

Employees86
Market Cap$1.52 billion
Next Earnings Date6/6/2019 (Estimated)
OptionableNot Optionable

Myovant Sciences (NYSE:MYOV) Frequently Asked Questions

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd (NYSE:MYOV) announced its quarterly earnings data on Thursday, February, 7th. The company reported ($1.04) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.98) by $0.06. View Myovant Sciences' Earnings History.

When is Myovant Sciences' next earnings date?

Myovant Sciences is scheduled to release their next quarterly earnings announcement on Thursday, June 6th 2019. View Earnings Estimates for Myovant Sciences.

What price target have analysts set for MYOV?

6 Wall Street analysts have issued 1 year price targets for Myovant Sciences' stock. Their forecasts range from $25.00 to $42.00. On average, they anticipate Myovant Sciences' stock price to reach $31.20 in the next twelve months. This suggests a possible upside of 45.7% from the stock's current price. View Analyst Price Targets for Myovant Sciences.

What is the consensus analysts' recommendation for Myovant Sciences?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences.

Has Myovant Sciences been receiving favorable news coverage?

News stories about MYOV stock have been trending somewhat positive this week, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Myovant Sciences earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.

Who are some of Myovant Sciences' key competitors?

What other stocks do shareholders of Myovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Exelixis (EXEL), Fate Therapeutics (FATE), Ocular Therapeutix (OCUL), Portola Pharmaceuticals (PTLA), Verastem (VSTM), ZIOPHARM Oncology (ZIOP), Bausch Health Companies (BHC), Pfizer (PFE), Obseva (OBSV) and Madrigal Pharmaceuticals (MDGL).

Who are Myovant Sciences' key executives?

Myovant Sciences' management team includes the folowing people:
  • Dr. Lynn Seely, Principal Exec. Officer, Pres & Exec. Director (Age 59)
  • Mr. Frank L. Karbe, Principal Financial & Accounting Officer (Age 50)
  • Mr. Matthew Lang, Gen. Counsel & Sec. (Age 42)
  • Ms. Julie Tran MBA, MSHR, VP of HR
  • Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 50)

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who are Myovant Sciences' major shareholders?

Myovant Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include RA Capital Management LLC (5.24%), BB Biotech AG (5.08%), Lord Abbett & CO. LLC (2.70%), Bank of New York Mellon Corp (0.52%), Emory University (0.18%) and Millennium Management LLC (0.06%). Company insiders that own Myovant Sciences stock include Ferreira Juan Camilo Arjona, Holdings Ltd Dexxon, Mark Altmeyer and Pharmaceuticals Interna Takeda. View Institutional Ownership Trends for Myovant Sciences.

Which institutional investors are selling Myovant Sciences stock?

MYOV stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Emory University. View Insider Buying and Selling for Myovant Sciences.

Which institutional investors are buying Myovant Sciences stock?

MYOV stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, RA Capital Management LLC, BB Biotech AG, First Manhattan Co., Lord Abbett & CO. LLC and BlackRock Inc.. Company insiders that have bought Myovant Sciences stock in the last two years include Holdings Ltd Dexxon, Mark Altmeyer and Pharmaceuticals Interna Takeda. View Insider Buying and Selling for Myovant Sciences.

How do I buy shares of Myovant Sciences?

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $21.41.

How big of a company is Myovant Sciences?

Myovant Sciences has a market capitalization of $1.52 billion. Myovant Sciences employs 86 workers across the globe.

What is Myovant Sciences' official website?

The official website for Myovant Sciences is http://www.myovant.com.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-3318-9709 or via email at [email protected]


MarketBeat Community Rating for Myovant Sciences (NYSE MYOV)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  293
MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe MYOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel